Inogen Inc (NASDAQ:INGN) – Analysts at William Blair lifted their Q3 2017 earnings per share estimates for Inogen in a research note issued on Thursday. William Blair analyst M. Kaczor now expects that the medical technology company will post earnings per share of $0.33 for the quarter, up from their prior estimate of $0.30. William Blair also issued estimates for Inogen’s FY2017 earnings at $1.23 EPS, Q1 2018 earnings at $0.24 EPS, Q3 2018 earnings at $0.40 EPS, Q4 2018 earnings at $0.33 EPS and FY2018 earnings at $1.39 EPS.

Several other research firms have also commented on INGN. Needham & Company LLC decreased their price target on shares of Inogen from $108.00 to $96.00 and set a “strong-buy” rating for the company in a research report on Thursday, June 8th. BidaskClub lowered shares of Inogen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Sidoti began coverage on shares of Inogen in a research report on Tuesday, April 18th. They set a “neutral” rating and a $79.00 price target for the company. Zacks Investment Research lowered shares of Inogen from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. Finally, Stifel Nicolaus increased their price target on shares of Inogen from $65.00 to $75.00 and gave the company a “hold” rating in a research report on Wednesday, May 10th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Inogen currently has a consensus rating of “Buy” and a consensus target price of $91.60.

ILLEGAL ACTIVITY NOTICE: “William Blair Comments on Inogen Inc’s Q3 2017 Earnings (INGN)” was first published by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/07/william-blair-comments-on-inogen-incs-q3-2017-earnings-ingn.html.

Inogen (INGN) opened at 91.08 on Monday. The company’s 50-day moving average is $94.52 and its 200-day moving average is $80.91. The stock has a market capitalization of $1.87 billion, a PE ratio of 81.47 and a beta of 1.01. Inogen has a 12 month low of $50.11 and a 12 month high of $97.71.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.10. Inogen had a net margin of 11.30% and a return on equity of 12.69%. The company had revenue of $64.10 million during the quarter, compared to analysts’ expectations of $59.99 million. During the same period last year, the company posted $0.25 EPS. Inogen’s revenue was up 17.4% on a year-over-year basis.

Several hedge funds have recently added to or reduced their stakes in INGN. Ameriprise Financial Inc. raised its stake in Inogen by 9.6% in the first quarter. Ameriprise Financial Inc. now owns 127,985 shares of the medical technology company’s stock valued at $9,927,000 after buying an additional 11,223 shares during the last quarter. Texas Permanent School Fund raised its position in shares of Inogen by 0.3% in the first quarter. Texas Permanent School Fund now owns 11,712 shares of the medical technology company’s stock valued at $908,000 after buying an additional 37 shares during the last quarter. Comerica Bank raised its position in shares of Inogen by 5.4% in the first quarter. Comerica Bank now owns 17,906 shares of the medical technology company’s stock valued at $1,497,000 after buying an additional 919 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Inogen by 13.6% in the first quarter. BNP Paribas Arbitrage SA now owns 3,091 shares of the medical technology company’s stock valued at $240,000 after buying an additional 370 shares during the last quarter. Finally, First Trust Advisors LP raised its position in shares of Inogen by 0.4% in the first quarter. First Trust Advisors LP now owns 29,267 shares of the medical technology company’s stock valued at $2,270,000 after buying an additional 114 shares during the last quarter.

In other Inogen news, EVP Alison Bauerlein sold 6,666 shares of the stock in a transaction dated Wednesday, May 10th. The shares were sold at an average price of $83.24, for a total transaction of $554,877.84. Following the completion of the sale, the executive vice president now directly owns 25,758 shares of the company’s stock, valued at $2,144,095.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Scott Wilkinson sold 23,437 shares of the stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $88.06, for a total transaction of $2,063,862.22. Following the sale, the insider now directly owns 54,088 shares of the company’s stock, valued at $4,762,989.28. The disclosure for this sale can be found here. Over the last three months, insiders have sold 87,848 shares of company stock valued at $7,831,966. Insiders own 5.31% of the company’s stock.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.